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EGFR: exon 19 del 17 12 3 - 1 16.6 > 24
EGFR: L858R 8 3 5 - - 9.7 14.6
KRAS: codon 12 mutations 20 - 9 9 2 3.8 15.5
KRAS: other mutations 4 - 1 2 1 1.2 3.3
Conclusion: The role of speciﬁc EGFR and KRAS genotype merits 
further continued investigation. As several trials of ﬁrst-line geﬁtinib 
or erlotinib near completion, the ability to combine mutation data and 
clinical outcomes from increasing numbers of chemotherapy-naïve 
patients in a web-based database may yield more powerful insight into 
roles of speciﬁc mutations and help guide treatment decisions. We an-
ticipate the addition of a number of patients from Japan and from other 
trials in the coming months.
D2-07 Molecular Targeted Therapy: Biomarkers, Thu, 12:30 - 14:15
Mechanisms of activating PI3K signaling in lung cancers that 
become resistant EGFR tyrosine kinase inhibitors
Engelman, Jeffrey A.; Zejnullahu, Kreshnik; Mitsudomi, Tetsuya; 
Hyland, Courtney; Park, Joon Oh; Lindeman, Neal; Gale, Christopher-
Michael; Zhao, Xiaojun; Christensen, James; Rogers, Rogers M.; 
Cappuzzo, Federico; Mok, Tony; Lee, Charles; Bruce, Johnson E.; 
Cantley, Lewis C.; Jänne, Pasi A. 
Massachusetts General Hospital Cancer Center, Boston, MA, USA
Background: Cancers that are sensitive to EGFR inhibitors down-
regulate Phosphoinositide 3-Kinase (PI3K) signaling in response to 
these drugs. Inhibition of PI3K signaling appears to be critical for ErbB 
inhibitors to induce cell death. Although lung cancers with EGFR mu-
tation often have initial impressive responses to EGFR inhibitors, they 
invariably develop resistance. In 50% of such patients, a single second-
ary mutation, a substitution of methionine for threonine at position 
790 (T790M), has been identiﬁed. EGFR T790M is sufﬁcient to cause 
geﬁtinib resistance and leads to persistent ERBB3/PI3K/Akt signaling 
in the presence of geﬁtinib. However, the mechanisms by which the 
other half of cancers becomes resistant remain unidentiﬁed. 
Methods: To identify novel mechanisms of resistance, we cultured 
highly sensitive EGFR mutant and ampliﬁed cell lines in the presence 
of increasing concentrations of geﬁtinib until resistant cell lines were 
produced. 
Results: We found that, unlike the parental cells, all of the resistant cell 
lines maintain PI3K signaling in the presence of getitinib. Some cell 
lines use ErBB3 (i.e. no change from the parental cell line), whereas 
others utilize new adaptor proteins. Blocking the new mechanisms of 
activating PI3K leads to cellular death in the resistant cell lines.
Conclusions: Cancers that become resistant to EGFR inhibitors acquire 
novel mechanisms for activating PI3K. Inhibiting these pathways may 
be effective methods for treating cancers with acquired resistance to 
EGFR inhibitors.
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Background and Aim: SNP´s of DNA repair genes as well as SNP´s 
in MDR1 a CCND1 genes should serve as predictors of response to 
chemotherapy in NSCLC. The aim of this study was to ﬁnd SNP´s, 
their variants and combinations and their correlations to the response 
and toxicity for various cytostatic schedules. 
Material and Methods: Patients were divided according to prescribed 
cytostatics.There were several segregations,one using groups of 
patients treated by cisplatin or carboplatin, and another one separating 
patients treated by taxanes or vinorelbine vs.treated by gemcitabine. 
SNP´s were screened in DNA isolated from peripheral blood with the 
help of cycling-gradient capillary electrophoresis technique (CGCE) 
and standard DNA sequencing of PCR products. The following set of 
SNP markers was screened in all patients: ERCC1 Asn118Asn (C/T), 
ERCC2/XPD Lys751Gln (A/C), ERCC2/XPD Asp312Asn (G/A), 
XRCC1 Arg399Gln (G/A), XRCC3 Thr241Met (C/T), CCND1 A870G 
and MDR1 C3435T.
Results: The SNP set was screened in a total of 80 NSCLC patients. 
The group consisted of 57 males and 23 females, aged from 27 - 78 
with median 59.9 years. Overall response rates of chemotherapy 
induced leucotoxicity suffering patients were higher than thosesuffering 
from chemotherapy induced anaemias and/or thrombocytopenias. For 
ERCC1 (Asn118Asn), homozygous genotype T/T is associated with 
higher response rate followed by genotype C/T. The T/T patients also 
responded better to regimens including carboplatin than cisplatin. For 
XRCC1 (Arg399 Gln), genotype G/A exhibited more frequent response 
to chemotherapy than homozygous G/G. For XRCC3 (Thr241Met), 
homozygous genotype C/C is associated with higher response rate 
compared to homozygous T/T genotype. The C/C patients responded 
better to regimens including cisplatin than carboplatin. For MDR1 
(Ile1145Ile/C3435T), homozygous genotype C/C is associated with 
higher response rate compared to homozygous T/T. For CCND1 
(Pro241Pro), homozygous genotype A/A is associated with higher 
response rate compared to homozygous G/G. CCND1 genotype is as-
sociated with higher tumour response rate to taxanes/vinorelbine-plati-
num regimens, while genotype G/A is more sensitive to gemcitabine-
platinum derivatives.
Combination of several polymorphic markers seems to deliver promis-
ing results in prediction of response as well as toxicity. It enables 
